Smoore, Distributors Move to Toss Cannabis Vape Price-Fixing Suit

Events
Feb.24
Smoore, Distributors Move to Toss Cannabis Vape Price-Fixing Suit
Several vape manufacturers and distributors, including Shenzhen Smoore Technology Co. Ltd., Smoore International Holdings, 3Win Corp., Jupiter Research LLC, Canna Brand Solutions, and Greenlane Holdings Inc., have filed motions seeking dismissal of consumer claims in consolidated antitrust litigation in the U.S. District Court for the Northern District of California.

Key Points

 

  •  Vape manufacturers and distributors seek dismissal of antitrust MDL claims.

 

  •  Defendants argue consumers lack standing in the distribution chain.

 

  •  Plaintiffs allege price-fixing tied to cannabis vape hardware.

 

  •  Motions challenge sufficiency of conspiracy and pricing allegations.

 

  •  Case is pending in the Northern District of California.

 


 

2Firsts, February 24, 2026

 

According to Law360, Vape manufacturers and distributors have moved to dismiss consumer antitrust claims in consolidated multidistrict litigation pending in the U.S. District Court for the Northern District of California.

 

In motions filed Friday, distributor defendants 3Win Corp., Jupiter Research LLC, Canna Brand Solutions and Greenlane Holdings Inc., along with manufacturers Shenzhen Smoore Technology Co. Ltd. and Smoore International Holdings, argued that plaintiffs have failed to establish standing or plausibly allege a price-fixing conspiracy.

 

The litigation concerns closed cannabis oil vaporization systems and related components. Plaintiffs allege that distributor defendants entered into agreements with manufacturer Smoore to create a price floor and restrict the purchase of competing products, resulting in higher prices for cannabis-filled vape products.

 

Defendants contend that they manufacture and distribute empty vape hardware, not cannabis-filled products, and that these constitute distinct markets. They argue that consumers are too far removed in the commercial chain to assert antitrust claims, as they do not directly participate in the relevant hardware markets.

 

The motions further assert that the third amended complaint fails to allege specific pricing practices, including the prices charged by manufacturers to distributors, by distributors to retailers, or the amounts ultimately paid by consumers. Defendants also argue that the complaint does not adequately allege market share or demonstrate that the alleged conduct foreclosed competition across the relevant California market.

 

Additionally, defendants maintain that although plaintiffs have refiled claims under California’s Cartwright Act following dismissal of federal antitrust claims, the relief sought relates to cannabis products that remain federally illegal.

 

The consolidated case, In re: CCell Closed Cannabis Oil Vaporization Systems and Components Products Litigation, includes four consumer actions and one retailer action. The court has not yet issued a decision on the dismissal motions.

 

(Cover Photo: Cover page of a U.S. District Court (N.D. California) filing showing Smoore defendants’ motion to dismiss in the closed cannabis oil vaporizer antitrust class action. Source: U.S. District Court for the Northern District of California public filing (via Law360).)

West Virginia Senate Backs Vape Tax Increase to Offset Income Tax Cut
West Virginia Senate Backs Vape Tax Increase to Offset Income Tax Cut
The West Virginia Senate approved a 10% personal income tax cut on February 22, 2026, with part of the revenue offset coming from increased excise taxes on vape and e-cigarette products.
News
Feb.23
Small ENDS Manufacturers Press FDA on Abuse Liability Standards as Agency Defines Pharmacological Review Framework
Small ENDS Manufacturers Press FDA on Abuse Liability Standards as Agency Defines Pharmacological Review Framework
At the third session of its PMTA roundtable, the FDA outlined its framework for assessing abuse liability in ENDS products, emphasizing the role of nicotine pharmacokinetics and product-specific data in APPH determinations. Small manufacturers questioned the high cost of clinical PK studies and the absence of defined numeric thresholds, while raising bridging strategies and PBPK modeling as potential alternatives.
Feb.11
Nicotine Becomes Second-Largest Revenue Source for Couche-Tard in Fiscal 2025
Nicotine Becomes Second-Largest Revenue Source for Couche-Tard in Fiscal 2025
Alimentation Couche-Tard reported that nicotine products accounted for 9% of total revenue in fiscal 2025, making it the company’s second-largest revenue source after fuel, according to its latest Business Strategy Update.
Market
Feb.19
Michigan Proposes 57% Vape Tax in $800M Revenue Plan
Michigan Proposes 57% Vape Tax in $800M Revenue Plan
Michigan Governor Gretchen Whitmer’s FY2027 executive budget proposes a new 57% wholesale tax on vaping products and oral nicotine items as part of a broader $800 million revenue package aimed at stabilizing Medicaid funding.
Regulations
Feb.23
FDA Details Carcinogenicity Tiering and ELCR Framework as Small Manufacturers Press for Predictability
FDA Details Carcinogenicity Tiering and ELCR Framework as Small Manufacturers Press for Predictability
During the “Toxicological Profile” session at FDA’s Feb 10 PMTA roundtable, officials outlined the carcinogenicity tiering system and Excess Lifetime Cancer Risk (ELCR) framework used in ENDS reviews under the APPH standard. Small manufacturers questioned database transparency, exposure assumptions, and the existence of clear compliance benchmarks. FDA reiterated toxicological risk is assessed case by case within a broader population-level determination.
Feb.11
FDA Commissioner Stresses “Predictability” as Science Chief Addresses Industry Uncertainty
FDA Commissioner Stresses “Predictability” as Science Chief Addresses Industry Uncertainty
FDA Commissioner Marty Makary briefly appeared at the February 10 PMTA roundtable, underscoring the importance of regulatory predictability. At the close of the session, Office of Science Director Matthew Farrelly responded to industry concerns over review uncertainty, stating the agency will issue a written summary of feedback, while reiterating that no fixed quantitative risk benchmark governs authorization decisions.
Feb.11